Dental management of patients on anti-thrombotic agents

Jeong Keun Lee
Department of Oral and Maxillofacial Surgery and Institute of Oral Health Science,
Ajou University Dental Hospital, Ajou University School of Medicine, Suwon, Korea

Abstract
(J Korean Assoc Oral Maxillofac Surg 2018;44:143-150)

The number of geriatric patients seeking dental service is ever-rising because of increased life expectancy, also with problem of increased chronic medical conditions. One of them are patients on anti-thrombotic medication. Bleeding complication after minor oral surgery by anti-thrombotic agents is of concerns to dentists on dental management of these patients. Risk and benefit of the anti-thrombotic agents must be weighed before initiating dental procedures, which should be established as a treatment guideline. Purpose of the paper is to optimize the management of the dental patients on anti-thrombotic medication via standardization of treatment protocol of such a patient.

Key words: Anti-thrombotic, Anti-coagulant, Anti-platelet, Minor oral surgery

I. Introduction

Thromboembolism in acute coronary syndrome or atrial fibrillation is largely prevented by anti-thrombotic agents\(^1\,^2\). However, bleeding complications related to these agents after minor oral surgery is of concern to dentists for dental management of these patients. Risks and benefits of the anti-thrombotic agents must be weighed before initiating dental procedures, which should be established as treatment guidelines. The purpose of this paper is to optimize the management of dental patients on anti-thrombotic medication via standardized treatment protocols. The target readership of the paper is undergraduate and postgraduate dental students, general dental practitioners, trainees and residents of oral and maxillofacial surgery, and oral and maxillofacial surgeons.

II. Background

Hemostasis occurs as a result of the interaction of the components of Virchow’s triad, namely endothelial cells, blood composition and vascular flow. Interplay of these three factors determines the chance of thrombotic accident. Arterial thrombosis is related to platelet-rich white clots, whereas venous thrombosis is related to fibrin-rich red clots\(^3\). Anti-thrombotic agents are classified into two categories, anti-platelets and anti-coagulants, which are listed in Table 1\(^4\).

While anti-platelet agents inhibit platelet aggregation, anti-coagulant agents block the coagulation cascade after platelet aggregation. Anti-platelet agents are useful for the prevention and treatment of platelet-rich white clot formation, whereas anti-coagulant agents prevent and treat venous thromboembolism. Currently popular anti-thrombotic agents in Korea will be discussed briefly.

1. Anti-platelet agents

1) Aspirin (Astrix)

Aspirin is an anti-inflammatory drug that inhibits the cyclooxygenase pathway of arachidonic acid, which is mobilized in the inner cellular membrane\(^5\). In inhibiting this pathway, aspirin also inhibits the production of thromboxane, making it a standard for treatment of ischemic heart diseases. It can be used as a single load or used in combination with clopidogrel.
in dual antiplatelet therapy (DAPT)\(^6,7\). There are more thromboembolic complications after discontinuation when aspirin is used for secondary prevention than when used for primary prevention\(^8,9\), which necessitates careful consideration of aspirin discontinuation, especially when it is used in secondary prevention of thromboembolic complication.

2) Clopidogrel (Plavix)

In contrast to aspirin, which impairs thromboxane-mediated platelet activation, clopidogrel is a purinergic receptor antagonist that inhibits binding of P2Y\(_{12}\) receptors on the platelet surface with adenosine diphosphate (ADP)\(^10\). It can be administered at a rate of 75 mg once a day for primary prevention. In cases of acute coronary syndrome, the initial loading dose is 300 mg, followed by a daily maintenance dose of 75 mg. In cases of secondary prevention, it is more effective in preventing thromboembolism when used concomitant with aspirin (DAPT).

3) New anti-platelet agents

(1) Prasugrel (Effient)/ticagrelor (Brilinta)

Clopidogrel is a prodrug whose bioactive form is created through enzymatic cleavage in the liver. Metabolism of clopidogrel through hepatic enzyme CYP2C19 into its active form is a time-consuming process, and clinical efficacy of clopidogrel is largely dependent on inter-individual differences caused by genetic variability of expression of the enzyme CYP2C19\(^11\). Prasugrel is the same type of prodrug as clopidogrel, but is less subject to genetic variability and rapidly becomes biologically active because of differences in the metabolic pathways\(^12,13\). Ticagrelor is different from clopidogrel or prasugrel, which are thienopyridines; it has a reversible inhibitory action against P2Y\(_{12}\) receptor. Ticagrelor exerts its action via binding to the P2Y\(_{12}\) receptor in a manner different from ADP, resulting in an allosteric antagonist\(^14\).

(2) V orapaxar (Zontivity)

Thrombin is a serine protease that exhibits the most potent platelet activation at subnanomolar concentrations, in contrast to ADP, which requires micromolar concentration to exhibit its action\(^15,16\). Thrombin action on platelets is mediated via platelet protease-activated receptors (PARs). V orapaxar exerts its action via binding to the P2Y\(_{12}\) receptor in a manner different from ADP, resulting in an allosteric antagonist\(^14\).

2. Anti-coagulants

1) Warfarin (Coumadin)

Warfarin is used where blood flow is relatively static, mak-
ing its use effective for treatment of deep vein thrombosis or pulmonary embolism and for prevention of stroke in patients with atrial fibrillation, valvular heart disease or artificial heart valves\textsuperscript{18}. Its effects are monitored using the prothrombin time/international normalized ratio (PT/INR). It is administered orally, with few days required for its full pharmacologic action, which lasts for about five days.

2) NOACs

The term NOACs refers to novel (new) oral anticoagulants, also called “non-vitamin K antagonist oral anticoagulants” and “directly acting oral anticoagulants” (DOAC). They exhibit rapid onset time and prompt withdrawal of the anticoagulation effect when stopped because of their rapid action and short half-lives, respectively\textsuperscript{19-22}. Their predictable anti-coagulative activity decreases the need for monitoring relative to that required during warfarin therapy. Despite relatively little data, they are known to have few drug interactions and are less affected by diet\textsuperscript{23}.

(1) Dabigatran (Pradaxa)

Dabigatran is an oral preparation directly inhibiting thrombin. It is currently the only NOAC that has an antidote, idarucizumab, which reverses the anti-coagulative action of dabigatran within minutes\textsuperscript{24}. The most reported adverse reaction of this drug is gastrointestinal (GI) upset\textsuperscript{25}. It is contraindicated in patients with mechanical prosthetic heart valves to avoid thromboembolic events\textsuperscript{26}.

(2) Rivaroxaban (Xarelto)

Rivaroxaban is the first direct factor Xa inhibitor of oral preparation that belongs to the same type as apixaban (Eliquis) and edoxaban (Savaysa, Lixiana). It inhibits factor X competitively and is dose-dependent in its efficacy. With fewer complications than warfarin, the most known complication with rivaroxaban is GI bleeding. Rivaroxaban, along with apixaban and edoxaban, exhibited superior effectiveness with equal or reduced risk of bleeding compared to warfarin\textsuperscript{27}.

III. Bleeding Risk Assessment

1. Bleeding tendency according to procedural differences

Significant bleeding after dental procedures is relatively rare in patients of continued anti-coagulant therapy. However, any bleeding complications after minor oral surgery are of concern to dentists. Bleeding complication means prolonged or excessive bleeding or bleeding not controlled by initial hemostasis. Relevant dental procedures and their respective postoperative bleeding risks are listed in Table 2\textsuperscript{19}. Those procedures that cause little bleeding are straightforward in patients on anti-thrombotic agents with use of standard practices to avoid bleeding. Dental procedures that are likely to cause bleeding are categorized as either low-risk or high-risk procedures. Careful patient selection according to this criteria helps prevent bleeding complications.

2. Bleeding tendency related to patients’ medical conditions

In general, the evidence-based guidelines published by American Academy of Neurology recommend that anti-thrombotic medication be continued without change in patients with ischemic cerebrovascular disease\textsuperscript{28}. Individual patients’ characteristics are an important consideration for assessment of risk and benefit. Patients with ischemic heart disease who did not undergo coronary stent surgery belong to the low-risk group, whereas patients with prosthetic heart valve concomitant with atrial fibrillation are considered high-risk. Likewise, those with mechanical prosthetic valve are of consideration because they are not candidates for NOACs\textsuperscript{26}. Concerned patients’ medical conditions that are prone to develop thrombo-embolism are listed up in Table 3\textsuperscript{29}.

3. Other considerations

Many clinical trials have revealed similar or lower incidence of major bleeding events among patients taking NOACs than among those taking warfarin\textsuperscript{30-32}. However, clinical experience indicates that that clots typically form quickly, but also become dislodged easily in patients on anti-coagulants. Meanwhile, anti-platelet medication may lead to delayed clotting after invasive procedures, but once formed, clots tend to be more stable in those patients on anti-platelets than in patients on anti-coagulant medication. Additional risk factors for postoperative bleeding are possible if the patient has decreased renal function, liver function, or bone marrow disorders\textsuperscript{33}. Some herbal and complementary medicines such as garlic may be related to bleeding risk. Recently, an ultra-high risk group was added to the classification of patients on anti-thrombotic agents by the Asian Pacific Association of Gastroenterology (APAGE) and the Asian Pacific Society for Digestive Endoscopy (APSDE)\textsuperscript{34}, which should be conferred by other guidelines including our own.
IV. Bleeding Risk Management

General dental management principles for patients on anti-thrombotic agents recommend following standard procedures to avoid causing bleeding. If the anti-thrombotic medication is not prescribed as a life-long medication, dental treatment may be delayed until after discontinuation of the medication. For patients with prosthetic metal heart valves or coronary stents, direct written instructions from the cardiologist are required to alter their anti-thrombotic medications. Analgesic medications such as aspirin, ibuprofen and diclofenac can exacerbate the bleeding risk of the patient and should be prescribed carefully.

The most useful hemostasis is local mechanical arrest, such as packing of open sockets with hemostatic material and sutures. There is no reason to interrupt anti-thrombotic medication if the patient is taking aspirin alone, because there is no evidence of higher bleeding risk in these patients than in non-antithrombotic patients. Scheduling elective procedures early in the day and week is recommended for patients on anti-thrombotic agents to allow time for bleeding control, in case of bleeding episodes.

1. Dental management of patients on anti-platelet agents

With no suitable test for measuring anti-platelet effects causing bleeding, it is common belief that dual antiplatelet medication tends to prolong bleeding compared to aspirin alone. However, it is recommended that dental management be given without altering antiplatelet medication for patients on aspirin alone or on DAPT. Patients who undergo a coronary artery stent surgery must keep their anti-platelet prescription for up to 12 months. Currently the most commonly used dual antiplatelet medi-

Table 2. Bleeding tendencies for each dental procedure

| Dental procedures with lowest risk of bleeding | Dental procedures with tendency of bleeding |
|-----------------------------------------------|--------------------------------------------|
| Local anesthesia by infiltration, intraligamentary or mandibular block | Simple extraction (1-3 teeth) |
| Local anesthesia by inferior alveolar nerve block or other regional nerve block | Incision and drainage for intraoral swellings |
| Basic periodontal examination | Detailed 6 point full periodontal examination |
| Supragingival scaling or plaque removal | Subgingival scaling and root surface instrumentation |
| Restorations with supragingival margins | Restorations with subgingival margins |
| Endodontic treatment | Gingival contouring |
| Impressions and other prosthetic procedures | Biopsies |
| Fitting and adjustment of orthodontic appliances | |

Revised from the Web site of Scottish Dental Clinical Effectiveness Programme [cited 2018 Jun 6]. Available from: http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf.

Table 3. Thromboembolic risk stratification

| Low thromboembolic risk (<5%) | High thromboembolic risk (≥5%) |
|--------------------------------|--------------------------------|
| Atrial fibrillation with a CHADS2 score of 0-2 | Atrial fibrillation with a CHADS2 score of 3-6 |
| Atrial fibrillation with a CHA2DS2-VASc score of 0-4 | Atrial fibrillation with a CHA2DS2-VASc score of 5-9 |
| Prosthetic heart valve without high-risk features | Prosthetic heart valve within 3 months of surgery or with high-risk features |
| Venous thromboembolism after 3 months of anticoagulation treatment | Venous thromboembolism within the past 3 months |
| Coronary stents after 1 year of antiplatelet therapy | Coronary stents placement within the past 1 year |

1CHADS2 score means congestive heart failure, hypertension, age ≥ 75 years, diabetes, and prior stroke/transient ischemic attack.
2Updated version of CHADS2 score.
3High-risk features include atrial fibrillation, prior thromboembolism, left ventricular ejection fraction ≤ 35%, mitral or tricuspid valve placement, ≥ 2 prosthetic valves, and older aortic ball or tilting disc valves.

Revised from the article of Hsueh et al. (Otolaryngol Head Neck Surg 2015;153:493-503) with original copyright holder’s permission.
cation is the combination of aspirin with clopidogrel. In such a case hemostasis may be delayed up to an hour, which will justify limitation of the initial treatment site, e.g., a single extraction or limitation of the subgingival scaling to three teeth before further procedures. For procedures with a higher risk of postoperative bleeding, staged treatments over separate visits and active engagement of local hemostatic measures is recommended.

There are occasions that require complex anti-thrombotic therapy. Patients with atrial fibrillation often have coexisting vascular disease such as ischemic heart disease. In such a coexisting diagnosis, combined medication is required with continued oral anticoagulation and platelet inhibitor therapy. In rare cases of triple drug combinations or other combinations such as aspirin with warfarin or clopidogrel with warfarin, the risk of postoperative bleeding is higher, which necessitates medical consultation with the prescribing physician.

2. Dental management of patients on warfarin or other vitamin K antagonists

The key recommendation for a patient on warfarin is that there is no alteration of the vitamin K antagonist medication with an INR below 4. If the patient’s INR is stable, INR checking within 72 hours before the dental procedure is acceptable, whereas INR should be checked no more than 24 hours before when INR is unstable. It should be kept in mind that stable INR means INR measurements had not been above 4 in the last two months. If the INR is over 4, the dental procedure should be delayed until correction by anticoagulation management by medical personnel. Additionally, limiting the initial treatment site or staging treatment over separate visits for procedures with higher risk of bleeding should be considered.

3. Dental management of patients on NOACs

The NOACs currently available in clinical use are either too sensitive or too insensitive to PT/INR test. However, monitoring of NOACs is less critical than that of warfarin because these drugs are more stable in anticoagulation. NOACs have a rapid onset time and short half-lives compared to warfarin, which makes their anti-coagulation activity minimized and suboptimal. In this respect, dental management of patients on NOACs is more predictable than that of those on warfarin. Although there have been few NOACs with available antidotes (with the exception of idarucizumab for dabigatran), the quickness of the anti-coagulation effect of NOACs necessitates less monitoring.

Although there is little published research on the bleeding risks concerning dental procedures for patients on NOACs, key recommendations fall into two categories. Patients who are expected to have dental procedures with a low risk of bleeding are recommended not to alter the anti-coagulant medication. Patient appointments are recommended early in the morning in spite of the peak concentration of drugs, because the bleeding complication, should it occur, could be managed adequately during surgery hours. Limitation of the initial treatment site and active local hemostasis follows the principles described above.

Patients on NOAC who have higher-risk procedures with respect to postoperative bleeding are recommended to skip the morning dose on the day of the dental appointment. If the NOAC prescription is once a day in the evening, patients should not miss the evening medication the night before the dental appointment. Early appointments are recommended to allow time to cope with possible unexpected bleeding complications. Staged treatment over separate visits is also a consideration for such patients. Consideration of active local hemostasis is the same as above. Detailed medication counseling concerning when to restart medication is as follows:

1) Rivaroxaban (once a day): Missed morning dose is followed by the next morning dose after normal dental procedure without any bleeding complication. For patients with evening dose, usual evening dose on the day of early dental procedure is accepted only when four hours of hemostasis is confirmed.

2) Dabigatran and apixaban (twice a day): For those who have missed morning dose, usual evening dose is accepted as long as four hours of hemostasis is confirmed.

3) No missing of subsequent doses is allowed unless an absolute emergency of bleeding.

In rare occasions of emergency situations in patients who have already taken a morning dose, it is advised that higher risk procedures be delayed until later in the day to allow levels of anti-coagulation to decrease.

4. Dental management of patients on injectable anti-coagulant agents

Although limited, patients with parenterally administered low molecular weight heparin (LMWH) may still be en-
countered in the dental office. These patients include some pregnant woman and patients diagnosed as venous thrombosis that already have cancer. Dalteparin and enoxaparin are available drugs that could administered once daily or twice a day\textsuperscript{45,46}. For patients using these drugs, medical consultation is necessary prior to dental procedures because there is no direct clinical evidence concerning dental treatment. Patients with chronic renal impairment may have kidney dialysis, during which patients are given heparinized dialysis solution. Dental procedures must be delayed until the following day.

5. Drug interactions between anti-thrombotic agents and other medications

Many drugs prescribed by dentists, such as antibiotics or analgesics, could show drug interaction. Drugs that could have possible interactions with anti-platelet agents or anticoagulant agents are listed in Table 4\textsuperscript{19}. Drugs known to increase the bleeding tendency are indicated with an up arrow (↑). Drugs that could decrease antiplatelet or anticoagulant potential, which will increase the patient’s thromboembolic risk, are indicated with a down arrow (↓).

### V. Epilogue

The number of geriatric patients seeking dental service is ever rising because of increased life expectancy in conjunction with increased chronic medical conditions. Patients on anti-thrombotic medication fall into this category; treatment guidelines of such patients were described in this review. The consensus meeting on anti-thrombotic agents held on Mar 24, 2018 at Seoul National University Dental Hospital by the Korean Association of Oral and Maxillofacial Surgeons justifies a future consensus paper on dental management of patients on anti-thrombotic medication. Dedicated to future treatment guideline, the author hopes this review will bridge the gap between the current medical environment and that of the near future presenting an official consensus on dental management of patients on anti-thrombotic medication.

### Table 4. Drug interactions of anti-thrombotic agents with drugs commonly prescribed by dentists\textsuperscript{19}

| Oral anticoagulants | Amoxicillin ↑ | Metronidazole ↑ | Erythromycin ↑ | Clarithromycin ↑ |
|---------------------|---------------|-----------------|----------------|-----------------|
| Warfarin            |               |                 |                |                 |
| Phenindione         |               |                 |                |                 |
| Acenocoumarol       | Aspirin ↑     | Ibuprofen ↑     | Diclofenac ↑   | Carbamazepine ↓ |
|                     |               |                 |                |                 |
| Oral antiplatelets  | Aspirin ↑     | Ibuprofen ↑     | Diclofenac ↑   |                 |
| Clopidogrel         | Aspirin ↑     | Ibuprofen ↑     | Diclofenac ↑   | Erythromycin ↓  |
|                     |               |                 |                | Carbamazepine ↓ |
|                     |               |                 |                | Flucloxazole ↓  |
|                     |               |                 |                | Omeprazole ↓    |
| Dipyridamole        | Aspirin ↑     | Ibuprofen ↑     | Diclofenac ↑   |                 |
| Presugrel           |               |                 |                |                 |
| Ticagrelor          |               |                 |                |                 |
| NOACs               |               |                 |                |                 |
| Apixaban            | Aspirin ↑     | Ibuprofen ↑     | Diclofenac ↑   | Carbamazepine ↓ |
| Dabigatran          |               |                 |                |                 |
| Rivaroxaban         |               |                 |                |                 |
| Injectable anticoagulants | Aspirin ↑ | Ibuprofen ↑ | Diclofenac ↑ | Carbamazepine ↓ |
| Dalteparin          |               |                 |                |                 |
| Enoxaparin          |               |                 |                |                 |

(NOACs: novel oral anticoagulants)

↑: drugs known to increase the bleeding tendency, ↓: drugs that could decrease antiplatelet or anticoagulant potential, which will increase the patient’s thromboembolic risk.

Revised from the Web site of Scottish Dental Clinical Effectiveness Programme [cited 2018 Jun 6]\textsuperscript{19}. Available from: http://www.sdcep.org.uk/wp-content/uploads/2015/09/SDCEP-Anticoagulants-Guidance.pdf.
Author’s Contributions

The author participated in study design, data collection, and in writing the manuscript.

Conflict of Interest

No potential conflict of interest relevant to this article was reported.

References

1. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, et al. Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of valvular heart disease of the European society of cardiology (ESC) and the European association for cardio-thoracic surgery (EACTS). Eur Heart J 2012;33:2451-96.
2. Camm AJ, Kirchhof P, Lip GY, Colonna C, Gersh BJ, Pisters R, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J 2010;31:1360-420.
3. Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: Virchow’s triad revisited. Anesth Analg 2012;114:275-85.
4. Classification of antithrombotic agents [Internet]. Seoul: KIMS (Korean Index of Medical Specialties) [cited 2018 May 4]. Available from: http://www.kimsonline.co.kr/ResCenter/bookinbook/view/54.
5. Coleman RA, Kennedy I, Humphrey PPA, Bunce K, Lumley P, Prostanoids and their receptor. In: Emmett JC, ed. Comprehensive medicinal chemistry: membranes and receptors. Oxford: Pergamon Press; 1990:643-714.
6. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol 2011;58:e44-122.
7. Lange RA, Hillis LD. The duel between dual antiplatelet therapies. N Engl J Med 2013;368:1356-7.
8. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Petren AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206-14.
9. Oscarsson A, Gupta A, Fredrikson M, Järhult J, Nyström M, Petersson E, et al. To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth 2015;115:493-503.
10. Dorsam RT, Kunapuli S. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004;113:340-5.
11. Cattaneo M. Response variability to clopidogrel: is tailored treatment subcommittee of the American academy of neurology. Neurology 2013;80:2065-9.
12. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
13. Mega JL, Close SL, Viviviot SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 2009;119:2553-60.
14. Birkeland K, Parra D, Rosenstein R. Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor. J Blood Med 2010;1:197-219.
15. Davi G, Patrono C. Platelet activation and atherothrombosis. New Engl J Med 2007;357:2482-94.
16. Furie B, Furie BC. Mechanisms of thrombus formation. New Engl J Med 2008;359:938-49.
17. de Souza Brito F, Tricoci P. Novel anti-platelet agents: focus on thrombin receptor antagonists. J Cardiovasc Transl Res 2013;6:415-24.
18. Warfarin sodium [Internet]. Bethesda (MD): American Society of Health-System Pharmacists [cited 2018 Jun 6]. Available from: https://www.drugs.com/monograph/warfarin-sodium.html.
19. Management of dental patients taking anticoagulants or antiplatelet drugs [Internet]. Dundee (Scotland): Scottish Dental Clinical Effectiveness Programme [cited 2018 Jun 6]. Available from: http://www.sdccep.org.uk/wp-content/uploads/2015/09/SDCCEP-Anticoagulants-Guidance.pdf.
20. Boehringer Ingelheim. Pradaxa 150 mg hard capsules [Internet]. Surrey (England): electronic Medicines Compendium (eMC) [cited 2018 May 22]. Available from: https://www.medicines.org.uk/emc/medicine/24839.
21. Bayer plc. Xarelto 20 mg film-coated tablets [Internet]. Surrey (England): electronic Medicines Compendium (eMC) [cited 2018 May 22]. Available from: http://www.medicines.org.uk/emc/medicine/25586.
22. Bristol-Myers Squibb-Pfizer. Eliquis 5 mg film-coated tablets [Internet]. Surrey (England): electronic Medicines Compendium (eMC) [cited 2018 May 22]. Available from: http://www.medicines.org.uk/emc/medicine/27220.
23. Heart matters [Internet]. British Heart Foundation [cited 2018 Jun 6]. Available from: https://www.bhf.org.uk/heart-mattersmagazine/medical/drug-cabinet/novel-anticoagulants.
24. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015;373:51-20.
25. Blommel ML, Blommel AL. Dabigatran etexilate: a novel oral direct thrombin inhibitor. Am J Health Syst Pharm 2011;68:1506-19.
26. Eikelboom JW, Connolly SJ, Bryan JL, Hylek EM, D’Arcey M, Hacke W, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:883-91.
27. Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol 2015;72:524-34.
28. Armstrong MJ, Cronseth G, Anderson DC, Biller J, Cucchiara B, Dafer R, et al. Summary of evidence-based guideline: perioperative management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the guideline development subcommittee of the American academy of neurology. Neurology 2013;80:2065-9.
29. Haas WD, Hwang PH, Abuzeid WM. Perioperative management of antithrombotic therapy in common otolaryngologic surgical procedures: state of the art review. Otolaryngol Head Neck Surg 2015;153:493-503.
30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Pisters R, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
31. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
32. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
33. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: coagulopathies from systemic disease. Br Dent J 2003;195:439-45.
34. Chan FKL, Goh KL, Reddy N, Fujimoto K, Ho KY, Hokimoto S, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian pacific association of gastroenterology (APAGE) and Asian pacific society for digestive endoscopy (APSDE) practice guidelines. Gut 2018;67:405-17.
35. McCormick NJ, Moore UJ, Meerchan JG. Haemostasis. Part 1: the management of post-extraction haemorrhage. Dent Update 2014;41:290-2, 294-6.
36. Surgical management of the primary care dental patient on antplatelet medication [Internet]. Liverpool: North West Medicines Information Centre [cited 2018 Jun 4]. Available from: www.app.dundee.ac.uk/tuith/Static/info/antiplatelet.pdf.
37. Napeñas JJ, Oost FC, DeGroot A, Loven B, Hong CH, Brennan MT, et al. Review of postoperative bleeding risk in dental patients on antplatelet therapy. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:491-9.
38. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 2012;141(2 Suppl):c326S-50S.
39. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):S46S-92S.
40. Surgical management of the primary care dental patient on warfarin [Internet]. Liverpool: North West Medicines Information Centre [cited 2018 May 22]. Available from: http://www.app.dundee.ac.uk/tuith/Static/info/warfarin.pdf.
41. Nematullah A, Alabousi A, Blanas N, Douketis JD, Sutherland SE. Dental surgery for patients on anticoagulant therapy with warfarin: a systematic review and meta-analysis. J Can Dent Assoc 2009;75:41.
42. British Medical Association, Royal Pharmaceutical Society of Great Britain. British National Formulary (BNF) 70. London: BMJ Group, Pharmaceutical Press; 2015.
43. Favaloro EJ, Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) 2012;22:329-41.
44. Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet 2013;52:69-82.
45. Pfizer. Fragmin 10,000 IU/0.4ml solution for injection [Internet]. Surrey (England): electronic Medicines Compendium (eMC) [cited 2018 May 22]. Available from: http://www.medicines.org.uk/emc/medicine/26894.
46. SANOFI. Clexane Forte Syringes [Internet]. Surrey (England): electronic Medicines Compendium (eMC) [cited 2018 May 22]. Available from: http://www.medicines.org.uk/emc/medicine/10054.